Coherus Biosciences Receives Nasdaq Deficiency Notice

An announcement from Coherus Biosciences ( (CHRS) ) is now available.

On June 30, 2025, Coherus Oncology, Inc. received a deficiency notice from Nasdaq due to its stock price falling below $1.00 for 30 consecutive business days, which is below the required minimum for continued listing. The company has until December 29, 2025, to regain compliance by maintaining a minimum closing bid price of $1.00 per share for 10 consecutive business days. If Coherus fails to meet this requirement, it may seek an additional compliance period or face potential delisting, with options to appeal any delisting determination.

The most recent analyst rating on (CHRS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Coherus Biosciences stock, see the CHRS Stock Forecast page.

Spark’s Take on CHRS Stock

According to Spark, TipRanks’ AI Analyst, CHRS is a Neutral.

The overall stock score reflects significant financial challenges, including declining revenues and high leverage, which are major risk factors. While there are promising growth prospects from the oncology focus and recent corporate events, the technical analysis indicates bearish trends. The valuation remains unattractive due to negative earnings and lack of dividends. Strategic initiatives and cost-saving measures offer some positive outlook, but financial stability and market penetration remain crucial.

To see Spark’s full report on CHRS stock, click here.

More about Coherus Biosciences

Coherus Oncology, Inc. operates in the biotechnology industry, focusing on developing and commercializing oncology therapeutics.

Average Trading Volume: 1,547,789

Technical Sentiment Signal: Strong Sell

Current Market Cap: $88.14M

Learn more about CHRS stock on TipRanks’ Stock Analysis page.